CVS Health (CVS): Valuation Insights Following Earnings Miss, Goodwill Charge, and Guidance Cut

CVS Health (CVS) shares responded after the company announced a sizable third-quarter net loss, a $5.7 billion goodwill impairment, and sharply reduced its full-year earnings guidance. Investors are weighing these updates and considering what they signal about near-term profitability.

See our latest analysis for CVS Health.

After tumbling on steep quarterly losses and that hefty goodwill impairment, CVS Health's 1-year share price return still stands at a robust 77.4 percent. This signals strong momentum despite recent volatility. The 1-year total shareholder return, which includes dividends, clocks in at an impressive 49.7 percent. This indicates that long-term investors have benefitted from both price gains and payouts, even as fresh challenges dampen near-term enthusiasm.

If CVS Health’s recent shakeup has you thinking more broadly about investing in the healthcare space, it might be the perfect moment to discover See the full list for free.

With the stock trading at a notable discount to analyst price targets and recent turmoil shaking up expectations, is this the moment to buy into CVS Health's future growth story or are all the risks already accounted for?

Most Popular Narrative: 9% Undervalued

CVS Health’s most widely followed valuation narrative places fair value at $86.20, notably above its last close of $78.44. This difference highlights the need for a closer look at the drivers behind that value claim.

Integration of recent and ongoing acquisitions (such as Aetna, Oak Street, and Signify Health) and vertical alignment between insurance, pharmacy, and care delivery provide substantial cross-selling and synergy opportunities. These factors support long-term operating margin and earnings growth as margin recovery initiatives gain traction.

Read the complete narrative.

What’s fueling this valuation? There is a vision involving major acquisitions working in harmony, operational synergies, and a fresh approach to growth. But just how ambitious are the earnings and margin forecasts at the heart of this story, and what must happen for these levers to deliver? Unpack the projected path to see why consensus believes CVS’s real value is still ahead.

Result: Fair Value of $86.20 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, persistent margin pressure in healthcare delivery and ongoing pharmacy reimbursement challenges could quickly undermine the bullish case for CVS Health’s recovery narrative.

Find out about the key risks to this CVS Health narrative.

Build Your Own CVS Health Narrative

If you'd rather dive into the numbers yourself or think you can come to a different conclusion, crafting your own perspective takes less than three minutes, so why not Do it your way

A great starting point for your CVS Health research is our analysis highlighting 3 key rewards and 4 important warning signs that could impact your investment decision.

Looking for More Smart Investment Ideas?

Don’t stop with CVS Health. The stock market’s biggest winners can fly under the radar, and your next opportunity might be just a click away.

• Tap into dependable income by checking out these 18 dividend stocks with yields > 3% with high yields and stable payouts.
• Seize growth potential by investigating these 27 AI penny stocks at the forefront of artificial intelligence innovation and transformation.
• Catch the market’s hidden gems and unlock value fast with these 842 undervalued stocks based on cash flows identified by rigorous cash flow analysis.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com